PMID- 12847624
OWN - NLM
STAT- MEDLINE
DCOM- 20040930
LR  - 20131121
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 24
IP  - 5
DP  - 2003 May
TI  - Glutathione-S transferase-pi expression in non small cell lung cancer in the 
      assessment of response to chemotherapy.
PG  - 493-8
AB  - OBJECTIVE: To determine the relation of glutathione-S transferase-pi (GST-pi) 
      expression and cisplatin resistance in non small cell lung cancer (NSCLC). 
      METHODS: This study was carried out on 61 patients who were admitted to Chest 
      Diseases Clinic, Ondokuz Mayis University, Samsun, Turkey, from 1997 to 1999. 
      Twenty-seven NSCLC patients out of 61 lung cancer cases whose biopsy specimens 
      were evaluated for GST-pi, received multiagent chemotherapy including cisplatin. 
      The correlations between GST-pi expression and age, sex, performance score, 
      histology, stage of the disease and response to chemotherapy were investigated. 
      RESULTS: There was a significant correlation between GST-pi expression and the 
      histological type of the disease (p<0.05). However, no significant relation was 
      found with age, sex, performance score or stage of the disease (p>0.05). 
      Glutathione-S transferase-pi staining characteristics of the 27 patients 
      receiving chemotherapy were: less than 10% in 3 patients (11.1%), 10-50% in 9 
      patients (33.3%) and more than 50% in 15 patients (55.5%). One of the 3 patients 
      (33.3%) with GST-pi staining percentage of less than 10%, 3 of 9 patients (33.3%) 
      with staining percentage of 10-50% and 4 out of 15 patients (26.6%) with staining 
      percentage of more than 50% had an objective response to chemotherapy. No 
      significant correlation was found between GST-pi expression and response to 
      chemotherapy in the 3 groups (p>0.05). CONCLUSION: Glutathione-S transferase-pi 
      expression might not always predict the response to combination chemotherapy 
      regimens containing cisplatin. Several other mechanisms may play a role in 
      cisplatin-resistance.
FAU - Unsal, Meftun
AU  - Unsal M
AD  - Department of Chest Diseases, Faculty of Medicine, Ondokuz Mayis University, 
      Samsun, Turkey. meftununsal@hotmail.com
FAU - Akpolat, Ilkser
AU  - Akpolat I
FAU - Kandemir, Bedri
AU  - Kandemir B
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*blood/*drug therapy/mortality
MH  - Cisplatin/*administration & dosage
MH  - Female
MH  - Glutathione Transferase/*blood
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/*blood/*drug therapy/mortality
MH  - Male
EDAT- 2003/07/09 05:00
MHDA- 2004/10/01 05:00
CRDT- 2003/07/09 05:00
PHST- 2003/07/09 05:00 [pubmed]
PHST- 2004/10/01 05:00 [medline]
PHST- 2003/07/09 05:00 [entrez]
PST - ppublish
SO  - Saudi Med J. 2003 May;24(5):493-8.